In patients with type 2 diabetes at high CV risk
Ozempic® reduced the risk of CV events within 2 years1,5*
Time to first confirmed major adverse CV event (MACE)5
Hazard ratio, 0.74 (95% CI, 0.58-0.95)
P<0.001 for noninferiority
P=0.02 for superiority†
8.9%
Placebo
+ SOC
6.6%
Ozempic®
+ SOC
Weeks since randomisation
Patients with event (%)
10
8
6
4
2
0
0
8
16
24
32
40
48
56
64
72
80
88
96
104
WHEN ADDED TO STANDARD OF CARE‡
VS PLACEBO5
Components of the composite primary outcome (MACE)1,5
Nonfatal stroke=–39%
Nonfatal MI=–26%
CV death=–2%
[HR=0.61 (95% CI,
0.38-0.99; P=0.04)]
[HR=0.74 (95% CI,
0.51-1.08; P=0.12)]
[HR=0.98 (95% CI,
0.65-1.48; P=0.92)]
CV=cardiovascular; CI=confidence interval;
SOC=standard of care; MI=myocardial infarction.
*When added to SOC.1
†Testing for superiority for the
primary outcome was not prespecified.5
‡SOC included oral antidiabetic treatments, insulin,
antihypertensives, diuretics and lipid-lowering therapies.8
x 
SUSTAIN 6: A 2-year CVOT for Ozempic®1
3297 PATIENTS1,5
Inclusion criteria:
T2D, HbA1c ≥7%
Age ≥60 years with at least
1 CV risk factor
OR
Age ≥50 years with
established CV disease
CVOT=cardiovascular outcomes trial; T2D=type 2 diabetes; CV=cardiovascular; SOC=standard of care; MI=myocardial infarction.
1:1:1:1 randomisation1
Primary composite outcome1,5
Randomisation to first
occurrence of:
CV death
Nonfatal MI
Nonfatal stroke
Treatment duration 2 years
Ozempic® 1 mg
Ozempic® 0.5 mg
Placebo 1 mg
Placebo 0.5 mg
Diabetes
and
CV SOC
x 
Ozempic®—clinically meaningful weight loss and glycaemic control at 2 years5
Weight reductions from baseline over 2 years5*
†P<0.001
Mean body weight (kg)
Change from baseline
Placebo 1 mg –0.5 kg
Placebo 0.5 mg –0.7 kg
Ozempic® 0.5 mg –3.6 kg†
Ozempic® 1 mg –4.9 kg†
Weeks since randomisation
Mean body weight at baseline: 92.1 kg
Patients also experienced significant HbA1c reductions at 2 years5
At 2 years, Ozempic® 1 mg* provided an HbA1c reduction of up
to 1.4% vs 0.4% for placebo* (P<0.001)
–1.4%
SIGNIFICANT WEIGHT LOSS
*When added to standard of care.1,5
93
92
91
90
89
88
87
0
1.0
0.0
–1.0
–2.0
–3.0
–4.0
–5.0
0
8
16
30
44
56
68
80
92
104
x 
Cardiovascular outcomes trials in type 2 diabetes: An overview
REWIND12
(dulaglutide vs placebo)
LEADER25,26
(liraglutide vs placebo)
EMPA-REG14,27
(empagliflozin vs placebo)
SUSTAIN 65
(semaglutide vs placebo)
MACE
MACE
MACE
MACE
RRR
RRR
RRR
RRR
12%
13%
14%
26%
P=0.026
P=0.01
P=0.004
P<0.001 for noninferiority
P=0.02 for superiority†
CV death*=–9%
[HR=0.91 (95% CI, 0.78-1.06; P=0.21)]
CV death=–22%
[HR=0.78 (95% Cl, 0.66-0.93; P=0.007)]
CV death=–38%
[HR=0.62 (95% Cl, 0.49-0.77; P<0.001)]
CV death=–2%
[HR=0.98 (95% Cl, 0.65-1.48; P=0.92)]
Nonfatal stroke=–24%
[HR=0.76 (95% CI, 0.61-0.95; P=0.017)]
Nonfatal stroke=–11%
[HR=0.89 (95% Cl, 0.72-1.11; P=0.30)]
Nonfatal stroke=24%
[HR=1.24 (95% Cl, 0.92-1.67; P=0.16)]
Nonfatal stroke=–39%
[HR=0.61 (95% CI, 0.38-0.99; P=0.04)]
Nonfatal MI=–4%
[HR=0.96 (95% CI, 0.79-1.16; P=0.65)]
Nonfatal MI=–12%
[HR=0.88 (95% Cl, 0.75-1.03; P=0.11)]
Nonfatal MI=–13%
[HR=0.87 (95% Cl, 0.70-1.09; P=0.22)]
Nonfatal MI=–26%
[HR=0.74 (95% CI, 0.51-1.08; P=0.12)]
Please note that CVOTs are different in trial designs. Therefore, results cannot be
used as a head-to-head comparison.
MACE=major adverse cardiovascular event; RRR=relative risk reduction; HR=hazard ratio; CI=confidence interval; MI=myocardial infarction;
*Includes deaths of unknown cause.
†Testing for superiority for the primary outcome was not prespecified.5
BASELINE CRITERIA
CVOTs
#passText,
#component-passText{
position: absolute;
text-align: center;
font-size: 12px;
top: 16px;
width: 281px;
left: 9px;
}
#actText,
#component-actText{
position: absolute;
text-align: center;
font-size: 12px;
top: 15px;
width: 100%;
left: -2px;
}
#presentationEngine #component-passText span,
#presentationEngine #passText span{
text-align: center;
font-family: 'Frutiger LT Cond';
font-size: 17px;
font-weight: 600;
color: #fff;
}
.wrapper-for-text{
position: absolute;
top: 0;
left: 0;
width: 100%;
height: 100%;
overflow: hidden;
}
#presentationEngine #component-actText span,
#presentationEngine #actText span{
text-align: center;
font-family: 'Frutiger LT Cond';
font-size: 17px;
font-weight: 600;
color: #fff;
}
.wrapper-for-filler{
position: absolute;
top: 0;
left: 0;
width: 247px;
height: 57px;
border-radius: 15px;
overflow: hidden;
}
#enhancedHtml .filler,
#component-enhancedHtml .filler{
position: absolute;
left: 0px;
width: 232px;
height: 100%;
border-radius: 15px;
overflow: hidden;
}
#enhancedHtml .handler,
#component-enhancedHtml .handler{
position: absolute;
left: 211px;
top: 5px;
width: 45px;
height: 48px;
}
.tabActive .move-left{
transform: translate(-196px,0);
}
.tabActive .move-right{
transform: translate(196px,0);
}
.move-left,
.move-right{
transition: transform 0.5s linear;
}
#handlerReverse,
#presentationEngine #sustainerData .tab.tabActive #handler{
visibility: hidden;
}
#handler,
#presentationEngine #sustainerData .tab.tabActive #handlerReverse{
visibility: visible;
}
.move-left,
.move-right{
transform: translate(0,0);
}
Baseline criteria
REWIND11,12
(dulaglutide vs placebo)
LEADER25,26
(liraglutide vs placebo)
EMPA-REG14,27
(empagliflozin vs placebo)
SUSTAIN 65,8
(semaglutide vs placebo)
CV RISK
31% established CVD
82% established CVD
99% established CVD
83% established CVD
CV HISTORY
PRIOR MI
16.2%
31%
47%
33%
HEART FAILURE
8.6%
18%
10%
24%
MEAN DIABETES
DURATION
9.5 years
13 years
>10 years
14 years
MEAN HbA1c
7.2%
8.7%
8.1%
8.7%
INSULIN USE
24%
44.6%
48%
58%
TRIAL DURATION
5.4 years
Mean 3.8 years
Mean 3.1 years
2 years